Skip to content
Home
About Us
Leadership
Scientific Advisory Board
Board of Directors
Technology
Pipeline
Pipeline overview
Osteoporosis
Hypoparathyroidism
SBS & Obesity
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
Contact Us
Home
About Us
Leadership
Scientific Advisory Board
Board of Directors
Technology
Pipeline
Pipeline overview
Osteoporosis
Hypoparathyroidism
SBS & Obesity
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
Contact Us
SVB Securities Global Biopharma Conference
February 16, 2023
February 16, 2023
8:00 am
Publications
Click here for Webcast
READ MORE
June 15, 2026
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
Read More »
April 14, 2026
Entera Bio Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
Read More »
March 4, 2026
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
Read More »
See all News
Automated page speed optimizations for fast site performance